Zeon’s elastomer materials business division posted sales of 104.73 billion yen ($730.50 million) in the first half (April-September) of the fiscal year ending March 31, 2024, down 6.0% year-on-year, and operating profit of 3.64 billion yen, down 60.9%. General-purpose synthetic rubber is on a recovery trend compared to the second half of fiscal 2022 (October-March). While Japanese domestic sales remained...
Zeon Corporation has posted a 6.1% year-on-year decline in sales to 185.44 billion yen ($1.23 billion), a 53.1% drop in operating income to 9.46 billion yen, a 46.6% decline in ordinary income to 13.03 billion yen, and a 40.5% drop in net income to 10.35 billion yen in the first half (April-September) of the fiscal year ending March 2024. In...
Japan Rubber Weekly sat down for an interview with Tetsuya Toyoshima, who assumed the position of president of Zeon Corporation on June 29. Toyoshima is set to focus on products with special characteristics that can only be produced by Zeon, and will also promote initiatives for carbon neutrality and work styles. In the elastomer materials business division, which focuses on...
Zeon will begin full-scale development of a new grade of AFL adhesive slurry for separator coating in its battery materials business as part of its efforts to expand its lineup of environmentally friendly products. The company has been globally marketing anode binder, cathode binder, heat-resistant binder for separator coating, and AFL adhesive slurry for separator coating for lithium-ion batteries, and...
Zeon reported a 5.8% year-on-year decline in net sales to 91.9 billion yen ($648.9 million), a 43.0% drop in operating income to 6.1 billion yen, a 35.8% drop in ordinary income to 8.3 billion yen, and a 33.0% drop in net income to 5.8 billion yen for the first quarter of the year ending March 2024. In the elastomer materials...
Zeon has recently invested in Knowledge Palette, a company which develops AI drug discovery technology using single-cell transcriptome analysis. Knowledge Palette applies the world’s most accurate single-cell transcriptome analysis technology (Quartz-Seq2) to acquire large-scale data on the state of disease-causing cells. By using this information and AI technology to elucidate the causes of disease outbreaks, the company aims to efficiently...
